[The use of isoosmolar contrast medium for lowering of rate and clinical significance of contrast-induced nephropathy in patients with diabetes mellitus].
As a contrast medium during percutaneous coronary intervention (PCI) we used iodixanol in 31 patients with diabetes mellitus and various degree of impairment of renal excretory function and amidotrizoate - in 12 patients with diabetes mellitus without clinical signs of renal involvement. Blood plasma creatinine (BPC) level was measured before and on days 3,5, and 10 after procedure. When iodixanol was used no significant differences of blood surem creatinine (BSC) levels before PCI and BPC levels before and on days 3,5,10 after PCI were obtained. When results of the use of iodixanol and amidotrizoate were compared pronounced advantage of iodixanol became evident (increment of BPC on days 3 and 5 after PCI were significantly higher in amidotrizoate group - 1,30 +/- 0,17 and 1,39 +/- 0,40 mg/dl, p=0,006; 1,33 +/- 0,19 and 1,42 +/- 0,41 mg/dl, p=0,016). Thus the use of iodixanol in patients with initial stages of chronic renal failure (with BSC 1,5 - 2,5 mg/dl) was sufficiently safe. The use of amidotrizoate in patients with diabetes mellitus even in the absence of signs of renal failure led to pronounced damage of the kidney which manifested as elevation of BPC levels on days 3, 5, and 10 after intervention.
Sulimov
V A
VA
Udovichenko
A E
AE
D003287:Contrast Media / Q000008:administration & dosage*; D048909:Diabetes Complications / Q000175:diagnosis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D014283:Triiodobenzoic Acids / Q000008:administration & dosage
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C044834:iodixanol